Yilu Li
Zhengzhou University
9 Papers
Yilu Li is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Gene modification strategies for next-generation CAR T cells against solid cancers.
TL;DR: In this review, innovative strategies to enhance CAR T cell function by improving target identification, persistence, trafficking, and overcoming the suppressive TME are summarized.
Relationship between telomere length and the prognosis of breast cancer based on estrogen receptor status: A Mendelian randomization study
TL;DR: Findings add to the evidence that long telomere could predict a poor prognosis of ER- breast cancer, especially with ER- Breast Cancer Association Consortium (BCAC) data.
Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation
Lijie Han,Haiyan Zhang,Ping Ma,Jie Peng,Yilu Li,Jiaying Wu,Yuanyuan Li,Jifeng Yu,Wei Li,Mengmeng Zhang,Jia-Bao He,Zhiping Fan,Wei-Min Wang,Lina Sang,Hui Sun,Qifa Liu,Yang Liu,Zhongxing Jiang +17 more
TL;DR: In this paper , an accumulated intestinal microbiota (AIM) score was generated, and patients were divided into low and high-score groups, and the AIM score was associated with a better 3-year cumulative overall survival (OS) as well as lower mortality than a high score.
Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1
Lijie Han,Yilu Li,Jiaying Wu,Jie Peng,Xiao-Lin Han,Hongmian Zhao,Chen-Ming He,Yuanyuan Li,Wei-Min Wang,Mengmeng Zhang,Yafei Li,Hui Sun,Haixia Cao,Lina Sang,Zhongxing Jiang,Jifeng Yu +15 more
TL;DR: In this paper , a study retrospectively investigated in which cycle measurable residual disease (MRD) is associated with prognosis in patients in first complete remission (CR1) of intermediate-risk acute myeloid leukemia (AML).
ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer
Yilu Li,Xiaomei Liao,Li Ma +2 more
TL;DR: A correlation was observed between high ER CC1 expression and poor patient prognosis and high ERCC1 expression also influences the efficacy of immunotherapy and chemotherapy.